Navigation Links
New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
Date:5/9/2008

Novel Pain Medicine Studied in Patients Following Bunionectomy

TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Many foot-surgery patients experience intense pain for several days following removal of a bunion, one of the most common foot surgeries. The investigational pain medication tapentadol provided significant relief for patients who had this surgery, compared to those treated with placebo. Treatment with tapentadol also resulted in patients reporting fewer gastrointestinal side effects compared to those treated with an older, prescription pain reliever, researchers announced today.

Results from a Phase 3 clinical study of tapentadol immediate release (IR) tablets, a novel, investigational, centrally acting oral analgesic, showed that patients receiving 50 mg, 75 mg, or 100 mg of the medication experienced significant relief in acute pain after bunionectomy, a standard foot surgery associated with predictable levels of moderate to severe pain.

The overall difference in the intensity of pain experienced by patients recovering from bunionectomy was examined over the first 12, 24, 48 and 72 hours after initiating treatment with tapentadol. All tapentadol IR treatment groups showed a statistically significant improvement in pain over patients who received placebo, over all of these time periods (P<0.001).

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) presented these new data in a poster session at the 27th Annual Scientific Meeting of the American Pain Society (APS) in Tampa, Florida.

Treatment with 100 mg of tapentadol IR resulted in 79 percent of patients experiencing at least a 30 percent improvement in pain intensity at 48 hours. This is comparable to the 78 percent of patients who experienced the same percentage of improvement with 15 mg of oxycodone IR. Compared with placebo, the incidence of adverse events was higher for tapentadol IR and oxycodone IR treatment groups with a dose-
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...HAM, Mass., May 12 /- Arbio...ed today that the Company has received,approval fr...f an,Investigational Device Exemption ("IDE") to b...ios, extracorporeal (outside the body) liver assis...ients suffering from,chronic liver disease., "We ...
(Date:5/12/2008)...ADELPHIA, May 12 /PRNewswire-USNewswire/ -- GlaxoS...International Group (BIG), a leading,academic brea...groups, the,Spanish Breast Cancer Cooperative Grou...hase III study that will examine the role of TYKER...ALTTO (Neoadjuvant Lapatinib and/or,Trastuzumab Tr...
(Date:5/9/2008)...KOK, Thailand, May 9 /PRNewswire-USNewswire/ -- An...for the Protection of Animals (WSPA),is on stand-b...struck,Myanmar to assess and then relieve the suff... depend on for food and their livelihoods., WSP...iculture,Organization of the United Nations (FAO) ...
(Date:5/9/2008)...l Pain Medicine Studied in Patients Following Buni...wswire/ -- Many foot-surgery,patients experience i...a,bunion, one of the most common foot surgeries. T...ided significant relief for patients who had this,...reatment with tapentadol,also resulted in patients...
Breaking Medicine Technology:Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 2Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 5TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 3TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 4TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 5TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 6TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 7Animals That Cyclone Survivors Depend on Need Help Now 2New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 3New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 4New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 5Cardiome to Hold Investor Update Call 8309 1Cardiome to Hold Investor Update Call 8309 2Cardiome to Hold Investor Update Call 8309 3Cardiome to Hold Investor Update Call 8309 4Ratcliff Promotes 11 Staff Members 8304 1Ratcliff Promotes 11 Staff Members 8304 2Fish Give Clues to Human Skin Color Changes 8302 1Fish Give Clues to Human Skin Color Changes 8302 2Schering Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock 8297 1
...3, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmace... Sunesis, Senior Vice President,Corporate Develop...,the C. E. Unterberg, Towbin Emerging Growth Confe...n New York, NY. , Interested parties may access th...sis website at <a target="_blank" href=,"http://ir...
...wire-FirstCall/ -- Auxilium,Pharmaceuticals, Inc. ...utive Officer and President, and Mr. Jim Fickensch...he 2007 CEUT Emerging,Growth Opportunities Confere...e Mandarin Oriental Hotel in New York City. Mr. An...pany and its product,pipeline at 4:30 PM Eastern T...
Other Medicine Technology:Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin,Emerging Growth Conference 2Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging,Growth Opportunities Conference 2Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging,Growth Opportunities Conference 3
(Date:5/12/2008)..., Hamilton, ON (May 12, 2008) - Beta-blocker drug...ut they may increase the risk of death and major s...oday by the prestigious medical journal, The Lance...l addressing perioperative cardiac complications. ...sus placebo given to patients around the time of s...
(Date:5/12/2008)... EAST LANSING, Mich., May 12 /PRNewswire-USNewsw...diagnostic radiologist, was installed as,president...ty (MSMS) during,the 143rd annual meeting of the M... graduate of the Wayne State University School of ...partment of Diagnostic Radiology at Henry,Ford Hos...
(Date:5/12/2008)... HARBIN, China, May 12 /Xinhua-PRNewswire-FirstC...letin Board: CYXI) ("China Yingxia" or "the,Compan...try engaged in the,development, manufacture and di...upplements, and personal care products in the Peop... will conduct a conference call,Friday, May 16, 2...
(Date:5/12/2008)... HealthPartners hosts nine physicians from Chong...12 /PRNewswire-USNewswire/ -- HealthPartners,Insti...jor medical,delegation of Chinese physicians ever ... the physicians will observe hospital- and clinic-...spital administration and,observe clinical researc...
Breaking Medicine News(10 mins):Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 2Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 3Health News:Michael A. Sandler, MD, Installed as President of Michigan State Medical Society 2Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:First Major Chinese Medical Delegation Visits Minnesota 2
...n classroom activities are more likely to demonstr... Furthermore, children excluded from classroom act...w withdrawal symptoms.// The results of this study...ology, a publication of the American Psychological...
... is all set for a plunge into politics by becoming...h's assembly elections.// Jahnabi Goswami is expec... assembly constituency in eastern Assam's Nagaon d...here. Former Assam chief minister Prafulla Kumar ...
...ave been successfully separated by Saudi Arabian d...al Guard// Medical City in Riyadh separated the co...y. The twins, Hafsa and Ilham had a conjoined abd...rinary tract and hip. Abdullah Al-Rabeeah, the he...
...ting weights, a new study shows. Weight lifting at...lating over your waist. In addition, it can ensure...y was conducted among nearly 164 obese or overweig...en ages 24 and 44 were divided into two groups. Th...
Other Medicine News:Health News:Peer Rejection Leads To Reduced Participation In Classroom Activities 2Health News:HIV-Positive Woman To Be Congress Candidate In Assam 2